<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782869</url>
  </required_header>
  <id_info>
    <org_study_id>2020-55</org_study_id>
    <secondary_id>ID-RCB</secondary_id>
    <nct_id>NCT04782869</nct_id>
  </id_info>
  <brief_title>Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epilepsy</brief_title>
  <acronym>GALVANI PS-1</acronym>
  <official_title>Personalized Multichannel Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epilepsy: Evaluation of Therapeutic and Neurophysiological Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to conduct a pilot study based on the targeting of the epileptogenic zone&#xD;
      previously localized very precisely by stereoelectroencephalography (SEEG). SEEG is used as&#xD;
      part of the pre-surgical assessment. It consists, thanks to the intracerebral implantation of&#xD;
      electrodes in the brain of patients, to perform an intracerebral electrophysiological&#xD;
      recording and thus to precisely explore the epileptogenic regions.&#xD;
&#xD;
      In order to study the neuromodulatory and therapeutic effects of tDCS on epileptic brains,&#xD;
      non-invasive techniques for measuring electrophysiological brain activity such as&#xD;
      magnetoencephalography (MEG) and high-resolution electroencephalography (HR EEG) will be&#xD;
      used.&#xD;
&#xD;
      Finally, since epilepsy is considered to be a disorder of brain functional networks&#xD;
      associated with disturbed brain connectivity, the effects of tDCS on cortical excitability by&#xD;
      studying the variations in functional connectivity induced by stimulation will be studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure frequency</measure>
    <time_frame>Comparison between baseline and month 2</time_frame>
    <description>Percentage of change of seizures frequency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizure frequency</measure>
    <time_frame>Comparison between baseline and month 4</time_frame>
    <description>Percentage of change of seizures frequency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizure frequency</measure>
    <time_frame>Comparison between baseline and month 6</time_frame>
    <description>Percentage of change of seizures frequency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizure frequency</measure>
    <time_frame>Comparison between baseline and month 8</time_frame>
    <description>Percentage of change of seizures frequency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Comparison between baseline and month 8</time_frame>
    <description>Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) - score to 6 to 24, higher values mean worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety disorders</measure>
    <time_frame>Comparison between baseline and month 8</time_frame>
    <description>Generalized Anxiety Disorder-7 (GAD-7) - score between 0 to 21, higher values mean worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizures evaluation</measure>
    <time_frame>Comparison between baseline and month 8</time_frame>
    <description>National Hospital Seizure Severity Scale (NHS3) - score 1 to 31, higher values mean worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain functional connectivity</measure>
    <time_frame>Comparison between day 1 and day 5 of each session</time_frame>
    <description>National Hospital Seizure Severity Scale (NHS3) score 1 to 31, higher values mean worse outcome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>tDCS (transcranial direct current stimulation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be treated for 3 cycles. A cycle is composed of 5 bi-sessions (one per day) of 20 minutes each.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial direct current stimulation</intervention_name>
    <description>Patients will be treated using Starstim 8 device, a device allowing to perform transcranial direct current stimulation. The position of electrodes will be personalized based on the localization of the epileptogenic zone.</description>
    <arm_group_label>tDCS (transcranial direct current stimulation)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Age: Older than 12 years old&#xD;
&#xD;
          -  Patients with drug-resistant focal epilepsy with no surgical indication or with a&#xD;
             previous surgical failure or refusing surgery.&#xD;
&#xD;
          -  SEEG previously performed before inclusion with an adequate definition of the&#xD;
             epileptogenic zone&#xD;
&#xD;
          -  A clinical or research MRI scan that is suitable for navigated brain stimulation (NBS)&#xD;
             and definition of target area.&#xD;
&#xD;
          -  Number of seizures &gt;3/month during the baseline (before the first session of tDCS&#xD;
             treatment), for at least 3 months&#xD;
&#xD;
          -  Have stable medications for the whole study duration and few weeks before&#xD;
&#xD;
          -  Total IQ&gt;65&#xD;
&#xD;
          -  Be able to understand, speak and write in French&#xD;
&#xD;
          -  Patient, parents or legally representative who have given written informed consent to&#xD;
             allow the study data collection procedures,&#xD;
&#xD;
          -  Be a beneficiary of affiliated to a health insurance plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Generalized epilepsy&#xD;
&#xD;
          -  Presenting contraindication to MRI, a serious intercurrent pathology, a progressive&#xD;
             brain tumor&#xD;
&#xD;
          -  Skin conditions (e.g., eczema, lesion)&#xD;
&#xD;
          -  Any cranial metal implants (excluding &lt;1 mm thick epicranial titanium skull plates and&#xD;
             dental fillings) or medical devices (i.e. cardiac pacemaker, deep brain stimulator,&#xD;
             medication infusion pump, cochlear implant).&#xD;
&#xD;
          -  Previous surgeries opening the skull leaving skull defects capable of allowing the&#xD;
             insertion of a cylinder with a radius greater or equal to 5 mm.&#xD;
&#xD;
          -  Metal inside the head (outside the mouth) such as shrapnel, surgical clips&#xD;
&#xD;
          -  Patient currently participating in another clinical trial or having participated in a&#xD;
             clinical trial in the month prior to inclusion.&#xD;
&#xD;
          -  Any condition that makes the study subject, in the opinion of the investigator,&#xD;
             unsuitable for the study.&#xD;
&#xD;
          -  Person protected by articles L1121-5, L1121-6 and L1121-8 of Public Health Code&#xD;
             (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations&#xD;
             of social fragility, adults unable or unable to express their consent).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Olivier Arnaud</last_name>
    <role>Study Director</role>
    <affiliation>AP-HM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice Bartolomei, MD, PhD</last_name>
    <phone>0491384638</phone>
    <phone_ext>+33</phone_ext>
    <email>fabrice.bartolomei@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service d'Epileptologie et de Rythmologie Cérébrale</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Bartolomei</last_name>
      <email>fabrice.bartolomei@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Stanislas Lagarde, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Scholly</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmaco-resistant epilepsy</keyword>
  <keyword>transcranial stimulation</keyword>
  <keyword>SEEG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

